November 2019 - Page 3 of 12

ThursdayNov 21, 2019 12:06 pm

Quest Patent Research Corp. (QPRC) Subsidiary Resolves Patent Dispute with AsusTek Computer Inc.

Wholly owned subsidiary Semcon IP Inc. resolves all claims and disputes by and between Semcon IP Inc. and AsusTek Computer Inc. relating to Semcon’s Power Management Portfolio Semcon’s licensing program has seen significant activity in 2019 with additional cases pending Trading on the OTCQB and with patent licensing revenues for the nine-months ended September 30, 2019, of approximately $2 million, QPRC offers investors an exciting opportunity to participate in the IP monetization space The Power Management/Bus Controller Portfolio, acquired by company Quest Patent Research Corp. (OTCQB: QPRC) from Intellectual Ventures in October 2015 and transferred to wholly owned subsidiary, Semcon…

ThursdayNov 21, 2019 11:35 am

ChineseInvestors.com Inc. (CIIX) CEO Describes Tremendous Opportunity in CBD-Cosmetics to China’s Market of 1.4 Billion Consumers

CIIX anticipates launch of hemp-infused wrinkle cream in China Through subsidiary CBD Biotech, CIIX will focus hemp and CBD products on the blooming Chinese market The company noted impressive sales, revenue growth for Q1 2020, greatly due to success of CBD Biotech ChineseInvestors.com Inc. (OTCQB: CIIX) CEO Warren Wang noted the enormous potential for cosmetics infused with industrial hemp in a RedChip Money Report interview. This sentiment was echoed in his letter to shareholders, where he noted that CBD-infused cosmetics will the company and its subsidiary, CBD Biotech, to a Chinese market of 1.4 billion people. CIIX plans to launch…

WednesdayNov 20, 2019 2:40 pm

OriginClear Inc. (OCLND) Driving Disruption of Trillion-Dollar Water-Treatment Industry

An estimated 20% of wastewater is treated globally, with much lower percentage being recycled OriginClear addresses situation by providing water-treatment and conveyance products that are installed on site CEO has goal for company to be driving force to take water industry from $1 trillion to a $5 trillion market In a world where an estimated 20% of wastewater globally is treated and a much lower percentage is recycled (http://nnw.fm/1oKPg), OriginClear Inc. (OTC: OCLND) may be key to the solution. A leading provider of water-treatment solutions, OriginClear is uniquely prepared to offer organizations of all types – hotels and resorts, real-estate…

WednesdayNov 20, 2019 2:19 pm

InsuraGuest Gains Firm Foothold on $57.669 Billion Vacation Rental Market with its State-of-the-Art InsurTech Guest Protection Platform

InsuraGuest’s guest protection policy, extended to each guest at check-in, covers accident damages, loss, and accidental medical The InsuraGuest™ InsurTech platform can integrate with 70 hotel and vacation rental property management systems Number of vacation rental users expected to top 297 million worldwide in 2019 Service-as-a-software (SaaS) company InsuraGuest Inc. has entered the rapidly growing vacation rental market with its proprietary software platform offering specialized insurance coverage to all guests from check-in to check-out. InsuraGuest’s innovative InsurTech platform protects guests during their stay at vacation rental properties in an industry that is expected to host more than 297 million total vacation…

WednesdayNov 20, 2019 1:45 pm

MCTC Holdings Inc. (MCTC) Advances Cannabinoid Delivery Research Efforts, Files Fourth High-Tech Patent

Most significant patent filed is also the most comprehensive, covering broad areas of cannabinoid polymeric nanoparticles and fibers Company is committed to continuing research program and expand its intellectual property portfolio over the coming months MCTC participating in multiple growing verticals within global cannabis industry through acquisitions, strategic partnerships, and intellectual property MCTC Holdings Inc. (OTC: MCTC), a cannabinoid science innovator focused on high-growth and high-margins sub-sectors of the cannabis and hemp industry, filed its fourth cannabinoid delivery technology patent. The patent broadly covers many aspects of nanoparticles and nano fibers comprising one or more cannabinoids disposed at least partially…

WednesdayNov 20, 2019 12:43 pm

Endonovo Therapeutics Inc.’s (ENDV) Electroceutical Device Brings Rapid Pain Relief, Leads to 30-40% Decrease in Post-Surgical Narcotic Prescriptions

Studies have shown a greater than 2.2-fold reduction in narcotic use over the first 48 hours post-op SofPulse (R) use causes 500% increase in new blood vessels, 59% increase in surgical wound recovery, 57% reduction in pain at one-hour post-op, 55% less pain medication and 50% less inflammation Bioelectric medicine is a $17 billion market, projected to exceed $33 billion annually by 2025 Commercial-stage developer of innovative medical devices Endonovo Therapeutics Inc.’s (OTCQB: ENDV) proprietary SofPulse(R) technology is being successfully used by surgeons at New Hanover Regional Medical Center (NHRMC) in North Carolina to reduce the volume of opioid prescriptions…

WednesdayNov 20, 2019 11:54 am

Plus Products Inc. (CSE: PLUS) (OTCQX: PLPRF) Announces Appointment of Ecommerce Exec to Board of Directors

Former Head of Digital Commerce at HSN, Jill Braff brings a wealth of experience in marketing, e-commerce to her new role CEO believes PLUS online CBD business will be transformative for the company Braff deems PLUS one of most promising companies in a high-growth industry Plus Products Inc. (CSE: PLUS) (OTCQX: PLPRF), a leading cannabis-branded product company with the two best-selling cannabis products in California, recently announced the appointment of ecommerce senior executive Jill Braff to the company’s board of directors (http://nnw.fm/K42zy). The move is aimed at further strengthening the company’s already impressive digital sales and marketing expertise. “We couldn’t…

TuesdayNov 19, 2019 12:44 pm

Predictive Oncology Inc.’s (NASDAQ: POAI) TumorGenesis Technology May Prove Critical in New Cancer Drug Development

Predictive Oncology subsidiary TumorGenesis developing new PDx models needed to understand the complexities of cancer Tremendous unmet need for patient-derived tumors (PDx) for new drug development - current mouse models unreliable TumorGenesis unique in the industry; its ovarian-cancer cells haven’t been widely available like most other PDx samples Multi-billion-dollar market opportunity As the precision-medicine industry continues to integrate technology to improve the efficiency and efficacy of its strategies, clinicians are realizing the need for actual patient samples to determine the best methods to defeat cancer. Researchers are now turning to patient-derived tumors (PDx) to better understand the complexities and vagaries…

TuesdayNov 19, 2019 12:08 pm

Quest Patent Research Corp. (QPRC) Completes Another Successful Licensing Campaign

Wholly owned subsidiary Mariner IC Inc. completes another successful licensing campaign around its Anchor Structure Portfolio Patent Licensing Revenues for the nine-months ended September 30, 2019 were approximately $2 million The company remains active in monetizing its existing portfolio as well as evaluating potential acquisitions QPRC trades on the OTCQB, offering investors an exciting opportunity to participate in the IP monetization space The Anchor Structure Portfolio, acquired by company Quest Patent Research Corp. (OTCQB: QPRC) from Intellectual Ventures in October 2015 and transferred to wholly owned subsidiary, Mariner IC Inc., consists of two United States patents which relate to technology…

TuesdayNov 19, 2019 11:04 am

Endonovo Therapeutics Inc. (ENDV) Offers Bright Spot in Opioid -Addiction Space with New Pain-Management Option

ENDV has developed a viable pain-control solution for those seeking alternatives to highly addictive opioids The company’s flagship product is an FDA-cleared, easy-to-place, noninvasive device that delivers pulsed electromagnetic frequencies to targeted area In one study, patients treated with Endonovo technology reported a decrease in pain medication by nearly threefold Amid mounting concern about the alarming opioid-addiction crisis, Endonovo Therapeutics Inc. (OTCQB: ENDV) offers one of the few bright spots on the horizon. Endonovo is the commercial-stage developer of noninvasive Electroceutical(TM) Therapeutic devices designed to target patient pain and inflammation, a viable pain-control solution for those desperately seeking options other than highly…

Financial news and publishing for public and private companies

Contact us: 212.418.1217

Month: November 2019